Teleflex Q2 revenue up 5.9% constant currency; revenue guidance raised, adjusted EPS maintained

TELEFLEX INC

2023-Q2 EPS reported $3.98 revenue$1,454,191,000

Q2 revenues $743.3M, +5.9% constant currency YoY; GAAP diluted EPS $2.35, adjusted diluted EPS $3.41.
FY2023 GAAP revenue growth guidance raised to 5.80%-6.55%; constant currency raised to 5.50%-6.25%.
FY2023 GAAP diluted EPS guidance lowered to $7.33-$7.93; adjusted diluted EPS maintained at $13.00-$13.60.
Announced acquisition of Palette Life Sciences AB for rectal spacer to expand Interventional Urology franchise.
Interventional Urology constant currency revenue declined 2.3% YoY; OEM segment grew 19.8% constant currency.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TELEFLEX INC reported the second quarter ended July 2, 2023 results: revenue $743.3 million, EPS $2.35. Guidance raised.

Period: the second quarter ended July 2, 2023
Revenue: $743.3 million
EPS: $2.35
Guidance: raised
Result: reported results

Exact text from the filing

Teleflex Reports Second Quarter Financial Results and Full Year 2023 Outlook Wayne, PA -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended July 2, 2023 . Second quarter financial summary • Revenues of $743.3 million, up 5.5% compared to the prior year period; up 5.9% on a constant currency basis • GAAP diluted EPS from continuing operations of $2.35, compared to $2.23 in the prior year period • Adjusted diluted EPS from continuing operations of $3.41, compared to $3.39 in the prior year period 2023 guidance summary • Raising GAAP revenue growth guidance to 5.80% to 6.55% • Raising the low end of constant currency revenue growth guidance to 5.50% to 6.25% • Lowering GAAP EPS from continuing operations guidance to $7.33 to $7.93 • Maintaining adjusted diluted EPS from continuing operations guidance of $13.00 to $13.60, reflecting estimated dilution from the acquisition of Palette Life Sciences AB

View on SEC.gov

Browse all earnings releases →

TELEFLEX INC filing history →

Source: SEC EDGAR

accession 0000096943-23-000088

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.